PDCD4 Negatively Regulated Osteogenic Differentiation and Bone Defect Repair of Mesenchymal Stem Cells Through

Yang Jiang1,2,3, Shuo Li1,4, Qian Zhou1,5

  • 1Hematology Department, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Insights

Programmed cell death 4 (PDCD4) negatively regulates mesenchymal stem cell (MSC) osteogenic differentiation. Knocking down PDCD4 enhances bone defect repair via the GSK-3β/β-catenin pathway, offering therapeutic potential for bone injuries.

Area of Science:

  • Stem cell biology
  • Regenerative medicine
  • Molecular biology

Background:

  • Mesenchymal stem cells (MSCs) are crucial for bone repair.
  • Programmed cell death 4 (PDCD4) influences MSC function.
  • PDCD4's role in osteogenic differentiation requires elucidation.

Purpose of the Study:

  • To investigate PDCD4's regulatory roles in MSC osteogenic differentiation.
  • To uncover the mechanisms underlying PDCD4's influence on bone defect repair.
  • To evaluate the therapeutic potential of modulating PDCD4 in MSCs.

Main Methods:

  • Knockdown of PDCD4 in human umbilical cord-derived MSCs using shRNA (shPDCD4-UCMSCs).
  • Flow cytometry for phenotype characterization and differentiation potential assessment.
  • In vivo rabbit bone defect model to evaluate therapeutic efficacy.

Main Results:

  • PDCD4 knockdown enhanced osteogenic differentiation and related molecule expression in UCMSCs.
  • PDCD4 knockdown increased GSK-3β phosphorylation and β-catenin expression.
  • shPDCD4-UCMSCs significantly improved bone defect healing in rabbits.

Conclusions:

  • PDCD4 acts as a negative regulator of MSC osteogenic differentiation via the GSK-3β/β-catenin pathway.
  • Targeting PDCD4 presents a promising strategy to enhance MSC-based bone injury therapies.